Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polymorphism of dextromethorphan oxidation in South Indian subjects.
Mamidi RN, Satyavageeswaran S, Vakkalanka SV, Chaluvadi MR, Katneni K, Brahmadevara N, Damodarram G, Subramaniam S. Mamidi RN, et al. Among authors: subramaniam s. Clin Pharmacol Ther. 1999 Aug;66(2):193-200. doi: 10.1053/cp.1999.v66.99989. Clin Pharmacol Ther. 1999. PMID: 10460073
Novel euglycemic and hypolipidemic agents. 1.
Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN, Reddy AK, Rajesh BM, Reddy PG, Chakrabarti R, Vikramadithyan RK, Rajagopalan R, Mamidi RN, Jajoo HK, Subramaniam S. Lohray BB, et al. Among authors: subramaniam s. J Med Chem. 1998 May 7;41(10):1619-30. doi: 10.1021/jm970444e. J Med Chem. 1998. PMID: 9572887
Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study.
Chatterjee A, Digumarti R, Mamidi RN, Katneni K, Upreti VV, Surath A, Srinivas ML, Uppalapati S, Jiwatani S, Subramaniam S, Srinivas NR. Chatterjee A, et al. Among authors: subramaniam s. J Clin Pharmacol. 2004 Jul;44(7):723-36. doi: 10.1177/0091270004265647. J Clin Pharmacol. 2004. PMID: 15199077 Clinical Trial.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: subramaniam s. Lancet Oncol. 2024 Apr 12:S1470-2045(24)00135-9. doi: 10.1016/S1470-2045(24)00135-9. Online ahead of print. Lancet Oncol. 2024. PMID: 38621400
Rhes, a striatal enriched protein, regulates post-translational small-ubiquitin-like-modifier (SUMO) modification of nuclear proteins and alters gene expression.
Rivera O, Sharma M, Dagar S, Shahani N, Ramĺrez-Jarquĺn UN, Crynen G, Karunadharma P, McManus F, Bonneil E, Pierre T, Subramaniam S. Rivera O, et al. Among authors: subramaniam s. Cell Mol Life Sci. 2024 Apr 8;81(1):169. doi: 10.1007/s00018-024-05181-8. Cell Mol Life Sci. 2024. PMID: 38589732 Free PMC article.
1,499 results